Hemab Therapeutics Holdings 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- As of September 30th, 2026, Hemab had $430.2 million in cash, cash equivalents, and marketable securities, compared with $457.5 million as of June 30th.
- Third-quarter 2026 R&D expenses were $24.6 million, compared with $14.6 million in the third quarter of 2025; G&A expenses were $5.1 million, compared with $2.5 million.
- Third-quarter net loss was $27.3 million, or $0.58 per share, compared with $17.1 million, or $18.04 per share, in the same period last year.
- Hemab initiated SOLARA, its pivotal Phase 3 trial of sotazumab in Glanzmann thrombocytopenia, and dosed the first participant in the Phase 1 trial of HMB-003.
- In Hemab’s Phase 2 extension study in Glanzmann thrombocytopenia, 92% of participants who bled during the run-in had fewer treated bleeds on sotazumab; mean high-intensity annualized treated bleed rate fell by 62%, and the low-dose weekly cohort’s mean annualized treated bleed rate fell by approximately 80%.
- In the HMB-002 Phase 1/2 trial, peak increases of approximately 2.5-fold in von Willebrand factor and factor VIII were reported, with normalized thrombin generation and aPTT and durability supporting potentially monthly dosing.
- In the sotazumab Phase 2b trial in Factor VII deficiency, two participants received a single subcutaneous dose; baseline prothrombin time of 180 seconds or more shortened by more than 50% in both.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Welcome to Hemab Therapeutics' third quarter 2026 conference call. Leading the call from management are Benny Sørensen, Chief Executive Officer, and Mads Behrndt, Chief Financial Officer. After management's prepared remarks, we will open the call to your questions. To ask a question during the session, you will need to press star one one on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star one one again. Please be advised that today's conference is being recorded. Before we get started, I would like to remind everyone that some of the comments that management may make on this call about the company's future expectations, plans, and prospects constitute forward-looking statements for purposes of the Safe Harbor provisions under the Private Securities Litigation Reform Act of 1995.
Actual results and events could differ materially from those expressed or implied in any forward-looking statements as a result of various important risks, uncertainties, and other factors, including those set forth in Hemab's most recent filings with the SEC, including its quarterly report on Form 10-Q for the quarterly period ended September 30, 2026, and any other future filings that the company may make with the SEC. Any forward-looking statement represents our view only as of today and should not be relied upon as representing our view as of any subsequent date. You are cautioned not to place any undue reliance on these forward-looking statements, and Hemab disclaims any obligation to update such statements, except as required by law. A replay of this call will be available on the Investor section of the Hemab website approximately two hours after the conclusion of the call.
I will now hand the call over to Benny Sørensen, Chief Executive Officer.
Thank you, operator, and thank you all for joining Hemab's first quarterly financial results call. We are glad you are here, and we look forward to using this forum every quarter to share our progress. At Hemab, we are developing targeted therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience. Our philosophy is simple: all patients matter, and people living with serious blood coagulation conditions should not have to live with inadequate treatment options. Let me start with the three pieces of news that matter the most for the coming months. First, yesterday, we announced the initiation of our pivotal phase III trial of sutacimig in Glanzmann thrombasthenia. Second, last week, we also announced the first clinical data from our phase II-B trial of sutacimig in Factor VII deficiency and new menstrual bleed data in non-human primates treated with HMB-003.
Updated data from the Factor VII deficiency trial will be presented at the ASH annual meeting on December 14, and the HMB-003 data on December 13. In February 2027, at the 20th EAHAD Congress, we will present new data from our HMB-002 program in von Willebrand disease. These updates follow a remarkable stretch for Hemab. Since our IPO in May, we have not slowed down. In July, we put our science on the global stage at ISTH with nine presentations and data updates across all three of our programs. We unveiled HMB-003 and dosed the first participant in our phase I trial, and we have now initiated SOLARA, our pivotal phase III trial of sutacimig in Glanzmann thrombasthenia. It is our first pivotal trial, and it is the first pivotal trial of a subcutaneous prophylactic treatment in Glanzmann thrombasthenia. Truly a defining moment for Hemab and for the Glanzmann community.
As we move into late-stage development, we are building the organization to match our ambition. In September, we welcomed Keli Walbert to our board. Keli brings two decades of commercial leadership, including launches of medicines for conditions ranging from rare to very common, making her the perfect strategic match. We have also begun building our commercial strategy and team so we can position ourselves to bring our medicines to patients as quickly as possible. Across our programs, we listen to patients' lived experience, we quantify the neglected unmet need, we apply our deep coagulation expertise, and we use validated technologies as well as high-quality clinical development strategies. We believe a different future is possible, one where prevention, not just management, becomes the standard of care. That vision comes to life across our first three programs.
Sutacimig is being developed for both Glanzmann thrombasthenia and Factor VII deficiency, with approximately 10,000 patients in our key markets. HMB-002 targets von Willebrand disease, the most common inherited bleeding disorder, with approximately 120,000 diagnosed patients in the same key markets. HMB-003 targets heavy menstrual bleeding, which affects more than 23 million women in the U.S. alone. I will walk through each program, Mads will review the financials, and then we will take your questions. HMB-003 is a fatty-acid-conjugated peptide that inhibits plasmin directly at its active site to stabilize clots. Preclinically, it showed greater activity than tranexamic acid, today's primary non-hormonal therapy for heavy menstrual bleeding. PK properties supporting potential once-per-cycle dosing, potentially offering an improvement over current short-acting therapies. We are initially developing HMB-003 for heavy menstrual bleeding, which has been called the missed vital sign, and is too often ignored.
It is reported in roughly one in three women of reproductive age, and is the leading cause of iron deficiency and anemia in this population. According to data compiled by Wellcome Leap, affected adult women miss an average of 3.6 weeks of work annually, costing the U.S. economy an estimated almost $100 billion. Millions of women and girls have no approved non-hormonal customized hemostatic treatment option for heavy menstrual bleeding, and that is the gap we are working to close with HMB-003. In September, we dosed the first participant in our randomized placebo-controlled single ascending dose phase I trial in healthy volunteers, which will inform dose selection and clinical development plans for HMB-003 in heavy menstrual bleeding and across additional high unmet need bleeding conditions. We expect initial clinical data from the phase I trial in mid-2027.
We have also announced new preclinical data from a cynomolgus monkey model of menstrual bleeding in which HMB-003 reduced the proportion of severe bleeding days and shifted bleeding towards lower intensity compared with baseline. We will present these data at ASH on December 13th. HMB-002 is a subcutaneous prophylactic monovalent antibody designed to shield von Willebrand factor from degradation, raising the body's own levels of both von Willebrand factor and factor VIII without compromising function. At ISTH, data from the VELORA Pioneer phase I/II trial showed clear proof of mechanism, and candidly, the results exceeded our own expectations. We had set a 1.5-fold increase as the target product profile, but we saw peak increases of approximately 2.5-fold in both von Willebrand factor and factor VIII, with normalized thrombin generation and APTT, and durability supporting potentially monthly dosing. Most adverse events were mild to moderate, with no serious or thrombotic events.
The single ascending dose portion was not designed to measure efficacy, so the early clinical observations were descriptive in nature. Still, we find them encouraging. Based on prospectively collected data, eight out of nine evaluable patients had zero treated bleeds in the 28 days after dosing, with a mean annualized treated bleed rate of 1.6 compared with a baseline mean of 20.1 prior to treatment. VELORA Discover continues its successful enrollment, with now 110 patients in prospective run-in and identified for future interventional trials. At EAHAD in February, we expect to present initial data from part B, monthly subcutaneous dosing at 150 milligram, and additional part A data from single dosing at 300 milligram. These data will cover patients with both type 1 and type 2A disease, adding data from eight to 10 new patients, with a total above 20 patients already.
Lastly, let me turn to sutacimig, a bispecific antibody that binds and stabilizes the body's own factor VIIa and recruits it to activated platelets to facilitate the formation of hemostatic plugs and control bleeding. In Glanzmann thrombasthenia, it holds Fast Track, Orphan Drug, and Breakthrough Therapy designations from the FDA, along with regulatory designations in Europe and the U.K. Starting with Factor VII deficiency, a severe bleeding disorder affecting about one in 500,000 people, where bleeds are recurrent, unpredictable, and potentially life-threatening. Our phase IIb trial is ongoing at a single site in the U.K. At ISTH, preclinical data showed binding to 22 of 25 tested severe to moderate factor VII variants, or 88%, supporting a broad patient applicability. Last week, we announced our first clinical data from the single ascending dose cohort.
As of July 24th, two participants with severe congenital Factor VII deficiency had received a single subcutaneous dose. Adverse events were low grade and assessed as not related to treatment. Baseline prothrombin time of 180 seconds or more shortened by more than 50% in both participants. In the participants with PK and PD data available, sutacimig produced sustained multifold accumulation of endogenous total factor VII, with exposure maintained through day 22. Updated data from all those participants will be presented at ASH on December 14th. Now, Glanzmann thrombasthenia. Here is the part that matters the most. There is no approved prophylactic treatment, and care today is reactive rather than preventive. The burden is felt week after week.
In Glanzmann's 360, an international natural history study, 88% of participants reported at least one bleed in the previous week, and 65% required a bleed-related hospital visit in the prior six months. These patients, or these people, they have kind of normalized living with unpredictable bleeds. Against that backdrop, our phase II extension data from ISTH gives us real conviction in this program. They showed sustained bleed reduction in 34 participants at a median of 6.9 months and up to 15.9 months of exposure. 92% of participants who bled during the run-in had fewer treated bleeds on sutacimig. The mean high-intensity annualized treated bleed rate was reduced by 62%, and in the low-dose weekly cohort, the mean annualized treated bleed rate fell by approximately 80%. There were no grade 3 or higher related adverse events.
Three participants had grade 2 thromboembolic events in higher exposure cohorts and/or with multiple risk factors, all managed with routine anticoagulation therapy. Based on these data, we have now initiated SOLARA, an open-label, single-arm, multicenter trial enrolling approximately 75 people with Glanzmann thrombasthenia aged 12 to 70 with at least four treated bleeds in the prior 12 months. After a 24-week run-in on current treatment, participants receive 48 weeks of once-weekly subcutaneous sutacimig at 0.2 milligrams per kilogram, a regimen chosen with the goal to optimize bleed reduction while avoiding the high peak exposures associated with the observed thromboembolic events. The primary endpoint compares the annualized treated bleed rate on sutacimig with the run-in period, with each participant serving as their own control. Secondary endpoints include high-intensity bleed rate, safety, tolerability, immunogenicity, and pharmacokinetics.
Participants who complete treatment will have the opportunity to continue sutacimig in a separate open-label extension study. SOLARA is being conducted under Hemab's active IND. SOLARA is designed as a single-arm trial using intra-patient comparisons. The FDA recommended that we consider a randomized controlled trial. However, the FDA acknowledged our concern about the feasibility of randomization in Glanzmann thrombasthenia. In light of substantial variability in treated bleed rates, the heterogeneity of the patient population, and the practical consideration of randomized trials in rare diseases, we've determined to proceed with the single-arm trial. SOLARA is a landmark for the Glanzmann thrombasthenia community. The first participants have been consented and are scheduled to enter the run-in before end of the year. With that, I'll hand it over to Mads.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
10 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
